Eleonora Minacapelli
University of Milan
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Eleonora Minacapelli.
BMC Neurology | 2014
Benedetta Goretti; Claudia Niccolai; Bahia Hakiki; Andrea Sturchio; Monica Falautano; Eleonora Minacapelli; Vittorio Martinelli; Chiara Incerti; Ugo Nocentini; Monica Murgia; Giuseppe Fenu; Eleonora Cocco; Maria Giovanna Marrosu; Elisabetta Garofalo; Ferdinando Ivano Ambra; Maurizio Maddestra; Marilena Consalvo; Rosa Gemma Viterbo; Maria Trojano; Nunzia Alessandra Losignore; Giovanni Bosco Zimatore; Erika Pietrolongo; Alessandra Lugaresi; Dawn Langdon; Emilio Portaccio; Maria Pia Amato
BackgroundBICAMS (Brief International Cognitive Assessment for Multiple Sclerosis) has been recently developed as brief, practical and universal assessment tool for cognitive impairment in MS subjects. It includes the Symbol Digit Modalities Test (SDMT), the California Verbal Learning Test-2 (CVLT2) and the Brief Visuospatial Memory Test-Revised (BVMT-R) . In this study we aimed at gathering regression based normative data for the BICAMS battery in the Italian population.MethodsHealthy subjects were consecutively recruited among patient friends and relatives. Corrections for demographics were calculated using multivariable linear regression models. Test-retest reliability was assessed using the Pearson correlation coefficient.ResultsThe BICAMS battery was administered to 273 healthy subjects (180 women, mean age 38.9 ± 13.0 years, mean education 14.9 ± 3.0 years). Test-retest reliability was good for all the tests.ConclusionsThe study provided normative data of the BICAMS for the Italian population confirming good test-retest reliability which can facilitate the use of the battery in clinical practice, also for longitudinal patient assessments.
Journal of Clinical Psychology in Medical Settings | 2016
Marta Bassi; Monica Falautano; Sabina Cilia; Benedetta Goretti; Monica Grobberio; Marianna Pattini; Erika Pietrolongo; Rosa Gemma Viterbo; Maria Pia Amato; Miriam Benin; Alessandra Lugaresi; Eleonora Minacapelli; Enrico Montanari; Francesco Patti; Maria Trojano; Antonella Delle Fave
This study jointly examined illness beliefs held by persons with multiple sclerosis (PwMS) and caregivers in relation to well-being. A group of 68 PwMS and their caregivers completed the Revised Illness Perception Questionnaire, Psychological Well-being Scales, Satisfaction with Life Scale and Positive Affect and Negative Affect Schedule. Findings revealed that PwMS’ well-being was primarily predicted by their own illness beliefs, and that also caregivers’ well-being was primarily predicted by their own beliefs. Across the two groups, well-being was positively associated with their belief that they understood the disease, and inversely associated with their representations of negative emotions. In addition, among PwMS, well-being was inversely associated with the number of symptoms they specifically attributed to their illness, while among caregivers, well-being was positively associated with beliefs that treatment could control the disease. Based on the study findings, psychoeducational and cognitive-behavioral strategies are suggested to promote well-being among PwMS and caregivers.
The Lancet Haematology | 2017
Andrés J.M. Ferreri; Kate Cwynarski; Elisa Jacobsen Pulczynski; Christopher P. Fox; Elisabeth Schorb; Paul La Rosée; Mascha Binder; Alberto Fabbri; Valter Torri; Eleonora Minacapelli; Monica Falautano; Fiorella Ilariucci; Achille Ambrosetti; Alexander Röth; Claire Hemmaway; Peter Johnson; Kim Linton; Tobias Pukrop; Jette Sønderskov Gørløv; Monica Balzarotti; Georg Hess; Ulrich Keller; Stephan Stilgenbauer; Jens Panse; Alessandra Tucci; Lorella Orsucci; Francesco Pisani; Alessandro Levis; Stefan W. Krause; Hans J. Schmoll
BACKGROUND The International Extranodal Lymphoma Study Group-32 (IELSG32) trial is an international randomised phase 2 study that addresses two key clinical questions in the treatment of patients with newly diagnosed primary CNS lymphoma. Results of the first randomisation have demonstrated that methotrexate, cytarabine, thiotepa, and rituximab (called the MATRix regimen) is the induction combination associated with significantly better outcome compared with the other induction combinations tested. Here, we report the results of the second randomisation that addresses the efficacy of myeloablative chemotherapy supported by autologous stem-cell transplantation (ASCT), as an alternative to whole-brain radiotherapy (WBRT), as consolidation after high-dose-methotrexate-based chemoimmunotherapy. METHODS HIV-negative patients (aged 18-70 years) with newly diagnosed primary CNS lymphoma and an Eastern Cooperative Oncology Group performance status of 0-3 were randomly assigned to receive four courses of methotrexate 3·5 g/m2 on day 1 plus cytarabine 2 g/m2 twice daily on days 2 and 3 (group A); or the same combination plus two doses of rituximab 375 mg/m2 on days -5 and 0 (group B); or the same methotrexate-cytarabine-rituximab combination plus thiotepa 30 mg/m2 on day 4 (group C), with the three groups repeating treatment every 3 weeks. Patients with responsive or stable disease after induction treatment, with adequate autologous peripheral blood stem-cell collection, and without persistent iatrogenic side-effects, were eligible for the second randomisation between WBRT (photons of 4-10 MeV; five fractions per week; fraction size 180 cGy; started within 4 weeks from the last induction course; group D) and carmustine-thiotepa conditioned ASCT (carmustine 400 mg/m2 on day -6, and thiotepa 5 mg/kg every 12 h on days -5 and -4, followed by reinfusion of autologous peripheral blood stem cells; group E). A permuted block randomised design was adopted for both randomisations, and a computer-generated randomisation list was used within each stratum. No masking after assignment to intervention was adopted. The primary endpoint was 2-year progression-free survival, with induction group and response to induction chemotherapy as stratification parameters. Analyses were done on a modified intention-to-treat basis. This study is registered with ClinicalTrials.gov, number NCT01011920. FINDINGS Between Feb 19, 2010, and Aug 27, 2014, 227 patients were recruited from 53 centres in five countries. 219 of 227 enrolled patients were assessable. Of the 122 patients eligible for the second randomisation, 118 patients were randomly assigned to WBRT or ASCT (59 patients per group) and constitute the study population. WBRT and ASCT were both effective, and achieved the predetermined efficacy threshold of at least 40 progression-free survivors at 2 years among the first 52 patients in both groups D and E. There were no significant differences in 2-year progression-free survival between WBRT and ASCT: 80% (95% CI 70-90) in group D and 69% (59-79) in group E (hazard ratio 1·50, 95% CI 0·83-2·71; p=0·17). Both consolidation therapies were well tolerated. Grade 4 non-haematological toxicity was uncommon; as expected, haematological toxicity was more common in patients treated with ASCT than in those who received WBRT. Two toxic deaths (infections) were recorded, both in patients who received ASCT. INTERPRETATION WBRT and ASCT are both feasible and effective as consolidation therapies after high-dose methotrexate-based chemoimmunotherapy in patients aged 70 years or younger with primary CNS lymphoma. The risks and implications of cognitive impairment after WBRT should be considered at the time of therapeutic decision. FUNDING Agenzia Italiana del Farmaco, Cancer Research UK, Oncosuisse, and Swiss National Science Foundation.
Multiple Sclerosis Journal | 2016
Ignazio Roberto Zarbo; Eleonora Minacapelli; Monica Falautano; Silvia Demontis; Giovanni Carpentras; Maura Pugliatti
Background: Personality traits can affect health-related quality of life (HRQoL) in different disorders. In multiple sclerosis (MS), personality traits can determine patients’ willingness to take on more risky treatment options, predispose to neuropsychiatric symptoms and affect coping strategies. Objectives: We investigated the role of personality traits as possible predictors of HRQoL in a large cohort of persons with MS (PwMS). Methods: In total, 253 consecutively recruited PwMS were screened for intellectual deficits with Raven Colour Progressive Matrices (RCPM), state anxiety with STAI-X1 and major depression on a clinical basis. PwMS’ self-perceived mental and physical health status was measured with the 36-Item Short Form Health Survey (SF-36), and the personality profile with the Eysenck Personality Questionnaire (EPQ-R). The correlation between HRQoL and personality traits was investigated by means of analysis of variance, adjusting for possible confounders. Results: Of the 253 MS patients, 195 (F:M=2.75), aged 41.7±10.2 years were included in the analysis. The variance of SF-36 mental and physical composite score was largely explained by extraversion and neuroticism. Conclusions: Our data confirm that PwMS’ HRQoL is largely influenced by personality traits, which may therefore act as predictors of perceived quality of life and should be included in clinical and experimental settings focusing on HRQoL.
Journal of Child and Adolescent Behavior | 2015
C. Bressi; Eleonora Minacapelli; Alessia Manzella; Giulia Aless; ra Capra; Elisabetta Dipasquale; Emanuela Paola Nocito
Background: The emotional-behavioral repertoire has been extensively studied in children and adolescents, devoting less effort to preadolescence. Objective: To investigate the emotional-behavioral repertoire compared to different sources of information – parents versus children – on a pilot non-clinical sample of Italian preadolescents. Methods: Thirty pre-adolescents aged 11 to 14 years old (16 females, 14 males) are consecutively referred to the Service of Psychotherapy, Ospedale Maggiore Policlinico, Milan for an evaluation of their mental health status. Pre-adolescents and their parents were respectively asked to fill in the Youth Self- Report (YSR) and the Child Behavior Check List (CBCL). Results: Significant differences between mothers and fathers emerged at Syndrome Scales (SSs): Anxious/ Depressed (p=0.026), Social Problems (p=0.035); at DSM-oriented Scales (DOSs) in Emotional Problems (p=0.012) and at the scales in Internalization (p=0.019). There are also significant differences on the total score (p=0.035). Comparing answers reported by pre-adolescents versus those reported by their parents, the number of scales with significant differences increases (SSs. Anxious/Depressed: p=0.032; Somatic Complaints: p=0.004; Thought Problems: p=0.010; DOSs. Anxiety Problems: p=0.044; Somatic Problems: p=.006; Internalization: p=0.016), with influences also the total score (p=0.049). Discreet correlations in all the global scales and in total scores between pre-adolescents and mothers, but not fathers, were found. Conclusions: Parents show differences in their perception of children’s emotional- behavioral problems, especially of internalizing behaviors. These results suggest the specific importance of an extended family analysis at this stage of development.
BMC Neurology | 2015
Claudia Niccolai; Emilio Portaccio; Benedetta Goretti; Bahia Hakiki; Marta Giannini; Luisa Pastò; Isabella Righini; Monica Falautano; Eleonora Minacapelli; Vittorio Martinelli; Chiara Incerti; Ugo Nocentini; Giuseppe Fenu; Eleonora Cocco; Maria Giovanna Marrosu; Elisa Garofalo; Ferdinando Ivano Ambra; Maurizio Maddestra; Marilena Consalvo; Rosa Gemma Viterbo; Maria Trojano; Nunzia Alessandra Losignore; Giovanni Bosco Zimatore; Erika Pietrolongo; Alessandra Lugaresi; Lorena Pippolo; Marco Roscio; A. Ghezzi; Debora Castellano; Sergio Stecchi
Blood | 2016
Andrés J.M. Ferreri; Kate Cwynarski; Elisa Jacobsen Pulczynski; Christopher P. Fox; Elisabeth Schorb; Paul La Rosée; Mascha Binder; Alberto Fabbri; Valter Torri; Eleonora Minacapelli; Monica Falautano; Fiorella Ilariucci; Achille Ambrosetti; Alexander Röth; Claire Hemmaway; Peter M Johnson; Kim Linton; Tobias Pukrop; Jette Sønderskov Gørløv; Monica Balzarotti; Georg Hess; Ulrich Keller; Stephan Stilgenbauer; Jens Panse; Alessandra Tucci; Lorella Orsucci; Francesco Pisani; Alessandro Levis; Stefan W. Krause; Hans-Joachim Schmoll
Neurology | 2014
Maria Pia Amato; Emilio Portaccio; Claudia Niccolai; Bahia Hakiki; Benedetta Goretti; Andrea Sturchio; Vittorio Martinelli; Monica Falautano; Eleonora Minacapelli; Ugo Nocentini; Chiara Incerti; Maria Giovanna Marrosu; Eleonora Cocco; Monica Murgia; Giuseppe Fenu; Ferdinando Ivano Ambra; Elisabetta Garofalo; Maurizio Maddestra; Marilena Consalvo; Giovanni Bosco Zimatore; Nunzia Alessandra Losignore; Alessandra Lugaresi; Erika Pietrolongo; Rosa Gemma Viterbo; Maria Trojano
Frontiers in Psychology | 2017
Antonella Delle Fave; Marta Bassi; Beatrice Allegri; Sabina Cilia; Monica Falautano; Benedetta Goretti; Monica Grobberio; Eleonora Minacapelli; Marianna Pattini; Erika Pietrolongo; Manuela Valsecchi; Maria Pia Amato; Alessandra Lugaresi; Francesco Patti
58th ASH Annual Meeting and Exposition: Session: 731. Clinical Autologous Transplantation | 2016
Kim Linton; Andres Jm Ferreri; Kate Cwynarski; Elisa Jacobsen Pulczynski; Christopher P. Fox; Elisabeth Schorb; Paul La Rosée; Mascha Binder; Alberto Fabbri; Valter Torri; Eleonora Minacapelli; Monica Falautano; Fiorella Ilariucci; Achille Ambrosetti; Alexander Röth; Claire Hemmaway; Peter M. Johnson; Tobias Pukrop; Jette Sønderskov Gørløv; Monica Balzarotti; Georg Hess; Ulrich auf dem Keller; Stephan Stilgenbauer; Jens Panse; Alessandra Tucci; Lorella Orsucci; Francesco Pisani; Alessandro Levis; S. W. Krause; Hans J. Schmoll